Biglycan Antikörper (AA 101-200)
Kurzübersicht für Biglycan Antikörper (AA 101-200) (ABIN872817)
Target
Alle Biglycan (BGN) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 101-200
- 
                                            Kreuzreaktivität
- Human, Maus, Kaninchen, Ratte
- 
                                            Homologie
- Dog,Cow,Sheep,Pig,Horse
- 
                                            Aufreinigung
- Purified by Protein A.
- 
                                            Immunogen
- KLH conjugated synthetic peptide derived from human Biglycan
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Applikationshinweise
- 
                        WB 1:300-5000
 ELISA 1:500-1000
 FCM 1:20-100
 IHC-P 1:200-400
 IHC-F 1:100-500
 IF(IHC-P) 1:50-200
 IF(IHC-F) 1:50-200
 IF(ICC) 1:50-200
- 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Konzentration
- 1 μg/μL
- 
                                            Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- 
                                            Konservierungsmittel
- ProClin
- 
                                            Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 
                                            Lagerung
- 4 °C,-20 °C
- 
                                            Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- 
                                            Haltbarkeit
- 12 months
 
- 
                                            
- 
    - 
                                            : "An Animal Model of Modic Changes by Embedding Autogenous Nucleus Pulposus inside Subchondral Bone of Lumbar Vertebrae."    in: Scientific reports, Vol. 6, pp. 35102, (2016)         (PubMed).        
 : "The effect of electroacupuncture on the extracellular matrix synthesis and degradation in a rabbit model of disc degeneration." in: Evidence-based complementary and alternative medicine : eCAM, Vol. 2014, pp. 731395, (2014) (PubMed).
 
 
- 
                                            : "An Animal Model of Modic Changes by Embedding Autogenous Nucleus Pulposus inside Subchondral Bone of Lumbar Vertebrae."    in: Scientific reports, Vol. 6, pp. 35102, (2016)         (PubMed).        
- 
    - Biglycan (BGN)
- 
                                            Andere Bezeichnung
- Biglycan
- 
                                            Hintergrund
- 
                        Synonyms: PGI, DSPG1, PG-S1, SLRR1A, Biglycan, Bone/cartilage proteoglycan I, BGN Background: The protein encoded by this gene is a small cellular or pericellular matrix proteoglycan that is closely related in structure to two other small proteoglycans, decorin and fibromodulin. The encoded protein and decorin are thought to be the result of a gene duplication. Decorin contains one attached glycosaminoglycan chain, while this protein probably contains two chains. For this reason, this protein is called biglycan. This protein plays a role in assembly of collagen fibrils and muscle regeneration. It interacts with several proteins involved in muscular dystrophy, including alpha-dystroglycan, alpha- and gamma-sarcoglycan and collagen VI, and it is critical for the assembly of the dystrophin-associated protein complex. 
- 
                                            Gen-ID
- 633
- 
                                            UniProt
- P21810
- 
                                            Pathways
- Glycosaminoglycan Metabolic Process
 Target
- 
                    
 
                                     
                                     
                                    